| Name | Title | Contact Details |
|---|
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
entrinsic bioscience is a recognized leader in the development, manufacturing and commercialization of disruptive, science-derived amino-acid technologies that are clinically-proven to deliver better health outcomes in a broad range of therapeutic areas including gut health, hydration, skin and respiratory health.
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation`s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical and biotechnology industries. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Medivation currently has 500+ employees located in beautiful downtown San Francisco, CA.
SimQuest is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.